Hepion Pharmaceuticals, Inc. (HEPA) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $1.53M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerHepion Pharmaceuticals, Inc. (HEPA) trades at $0.1312. Hepion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for chronic liver diseases. Market cap: $1.53M, Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for HEPA: HEPA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
Hepion Pharmaceuticals, Inc. (HEPA) Healthcare & Pipeline Overview
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of Rencofilstat, a cyclophilin inhibitor for treating non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. The company focuses on addressing unmet medical needs in liver disease through targeted drug therapies.
What Is the Investment Thesis for HEPA?
Hepion Pharmaceuticals presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's primary value driver is the successful development and commercialization of Rencofilstat for NASH, a large and growing market with limited treatment options. Positive Phase 2 clinical trial results for Rencofilstat would serve as a major catalyst, potentially leading to partnerships or acquisition. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and competition from larger pharmaceutical companies with more resources. With a market cap of $1.53M and negative P/E ratio, Hepion's valuation is highly dependent on the future success of Rencofilstat. Investors should carefully consider the inherent risks and uncertainties associated with clinical-stage biopharmaceutical companies before investing.
Based on FMP financials and quantitative analysis
HEPA Key Highlights
Rencofilstat, Hepion's lead drug candidate, has completed Phase 2a clinical trials.
- Hepion is focused on developing treatments for non-alcoholic steatohepatitis (NASH), a significant unmet medical need.
- Rencofilstat targets multiple pathologic pathways involved in the progression of liver disease.
- The company is conducting nonclinical studies to assess Rencofilstat's potential to reduce liver fibrosis and hepatocellular carcinoma tumor burden.
- Rencofilstat has demonstrated antiviral activities towards hepatitis B, C, and D viruses.
Who Are HEPA's Competitors?
HEPA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| COCH Envoy Medical, Inc. | $6.50 | +9.15% | $48.3M | — |
| ENVB Enveric Biosciences, Inc. | $1.38 | -1.43% | $6.07M | 30 5-pillar |
| LIXT Lixte Biotechnology Holdings, Inc. | $7.21 | -6.00% | $89.1M | — |
| RLYB Rallybio Corporation | $16.65 | +0.06% | $88.5M | 82 5-pillar |
| ICCC ImmuCell Corporation | $10.24 | -0.10% | $93.6M | 78 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.08 | -1.21% | $170M | 75 5-pillar |
| NAGE Niagen Bioscience Inc | $2.44 | +0.41% | $190M | 70 5-pillar |
| QTTB Q32 Bio Inc. | $8.45 | -2.31% | $252M | 67 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HEPA's Key Strengths?
Proprietary drug candidate (Rencofilstat) with a novel mechanism of action.
- Clinical-stage development with Phase 2a data.
- Focus on a large and growing market (NASH).
- Experienced management team with expertise in liver disease.
What Are HEPA's Weaknesses?
Limited financial resources.
- Reliance on a single drug candidate.
- High risk of clinical trial failure.
- Competition from larger pharmaceutical companies.
What Could Drive HEPA Stock Higher?
Announcement of Phase 2b clinical trial results for Rencofilstat in NASH.
- Advancement of Rencofilstat into Phase 3 clinical trials.
- Potential for partnerships or collaborations with larger pharmaceutical companies.
- Expansion of Rencofilstat into other liver disease indications.
What Are the Key Risks for HEPA?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for Rencofilstat.
- Regulatory hurdles in obtaining approval for Rencofilstat.
- Competition from other NASH treatments.
- Limited financial resources.
- Patent expiration for Rencofilstat.
What Are the Growth Opportunities for HEPA?
- Expansion of Rencofilstat into other liver diseases: Hepion has the opportunity to expand the use of Rencofilstat beyond NASH to treat other chronic liver diseases, such as liver fibrosis and hepatocellular carcinoma. Successful clinical trials in these areas could significantly increase the value of Rencofilstat and Hepion Pharmaceuticals.
- Partnerships and collaborations: Hepion can pursue partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of Rencofilstat. These partnerships could provide Hepion with access to additional funding, expertise, and resources, increasing the likelihood of success. The timeline for securing such partnerships is dependent on clinical trial results and market interest.
- Geographic expansion: Hepion can expand its geographic reach by conducting clinical trials and seeking regulatory approval for Rencofilstat in other countries. This would allow Hepion to tap into new markets and increase its revenue potential. The timeline for geographic expansion is dependent on regulatory approvals and market conditions.
- Development of new drug candidates: Hepion can leverage its expertise in liver disease to develop new drug candidates that target different pathways involved in the progression of liver disease. This would diversify Hepion's product pipeline and reduce its reliance on Rencofilstat. The timeline for developing new drug candidates is dependent on research and development efforts and clinical trial results.
- Orphan drug designation: Hepion can seek orphan drug designation for Rencofilstat in certain rare liver diseases. Orphan drug designation provides certain benefits, such as market exclusivity and tax credits, which can incentivize the development of treatments for rare diseases. The timeline for obtaining orphan drug designation is dependent on regulatory review and approval.
What Are HEPA's Competitive Advantages?
- Proprietary cyclophilin inhibitor technology with potential for broad application in liver diseases.
- Clinical-stage asset with Phase 2a data demonstrating efficacy and safety.
- Strong intellectual property protection for Rencofilstat.
- Expertise in liver disease biology and drug development.
What Does HEPA Do?
Hepion Pharmaceuticals, Inc., founded in 2013 and headquartered in Edison, New Jersey, is a biopharmaceutical company dedicated to developing innovative therapies for chronic liver diseases. Originally incorporated as ContraVir Pharmaceuticals, Inc., the company rebranded as Hepion Pharmaceuticals in July 2019 to reflect its sharpened focus on liver disease treatments. The company's lead drug candidate, Rencofilstat, is a cyclophilin inhibitor that has completed Phase 2a clinical trials. Rencofilstat targets multiple pathologic pathways involved in the progression of liver disease, including non-alcoholic steatohepatitis (NASH). Hepion is currently in clinical-phase development for NASH and conducting nonclinical studies to assess Rencofilstat's potential to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Furthermore, Rencofilstat has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. Hepion's research and development efforts are centered on addressing the significant unmet medical needs in the treatment of chronic liver diseases, offering potential therapeutic solutions for patients worldwide.
What Products and Services Does HEPA Offer?
- Develop drug therapy treatment for chronic liver diseases.
- Focus on non-alcoholic steatohepatitis (NASH) treatment.
- Develop Rencofilstat, a cyclophilin inhibitor.
- Conduct clinical trials to evaluate the safety and efficacy of Rencofilstat.
- Conduct nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden.
- Explore antiviral activities towards hepatitis B, C, and D viruses.
How Does HEPA Make Money?
- Develop and license or commercialize novel therapeutics for liver diseases.
- Conduct research and development to identify and validate new drug targets.
- Out-license or partner with larger pharmaceutical companies for late-stage development and commercialization.
- Generate revenue through licensing fees, milestone payments, and royalties.
What Industry Does HEPA Operate In?
The biotechnology industry is characterized by high risk and high reward, with companies like Hepion Pharmaceuticals focused on developing innovative therapies for unmet medical needs. The NASH market is a significant area of interest, driven by the increasing prevalence of obesity and diabetes. Competition is intense, with larger pharmaceutical companies and smaller biotechs vying for market share. Success in this industry requires strong scientific expertise, successful clinical trials, and effective regulatory strategies. The industry is subject to stringent regulatory oversight and lengthy development timelines.
Who Are HEPA's Key Customers?
- Patients with chronic liver diseases, particularly NASH.
- Hospitals and clinics that treat liver diseases.
- Pharmaceutical companies seeking to expand their liver disease portfolios.
- Research institutions and universities involved in liver disease research.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Forward Outlook
Wall Street analysts project Hepion Pharmaceuticals, Inc. revenue of about $0 for fiscal 2026, with EPS near $-472.00.
Earnings Track Record
Hepion Pharmaceuticals, Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 65.3% above estimates on average.
Financial Health
Hepion Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Hepion Pharmaceuticals, Inc. (HEPA) Valuation Context
Valued at $1.53M, HEPA is classified as a micro-cap stock.
Company Profile
Hepion Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Morristown, US. HEPA has traded publicly since 2014.
HEPA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary drug candidate (Rencofilstat) with a novel mechanism of action.
- Clinical-stage development with Phase 2a data.
- Focus on a large and growing market (NASH).
- Experienced management team with expertise in liver disease.
Bear Case
- Limited financial resources.
- Reliance on a single drug candidate.
- High risk of clinical trial failure.
- Competition from larger pharmaceutical companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HEPA Latest News
No recent news available for HEPA.
HEPA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for HEPA.
Price Targets
Wall Street price target analysis for HEPA.
HEPA MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for HEPA; grades run from A+ (80-100) to F (below 30).
Leadership: Kaouthar Lbiati
Unknown
Without additional context, it is impossible to provide details about their career history, education, or previous roles.
Track Record: Information on Kaouthar Lbiati's track record is not available in the provided data. It is not possible to assess their achievements, strategic decisions, or company milestones under their leadership without more information.
HEPA OTC Market Information
HEPA trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
HEPA Healthcare Stock FAQ
Is HEPA a good stock to buy?
Stock Expert AI does not rate HEPA buy, sell or hold. Hepion Pharmaceuticals, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the HEPA stock price today?
The last price recorded on this page for Hepion Pharmaceuticals, Inc. (HEPA) is $0.1312, as of the Oct 26, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about HEPA stock?
Without analyst reports or ratings, it is not possible to provide a summary of analyst consensus, key valuation metrics, or growth considerations. The company's valuation is currently dependent on the future success of Rencofilstat.
What are the key factors to evaluate for HEPA?
Evaluate HEPA on fundamentals, analyst consensus, and risk factors. With a market cap of $1.53M and negative P/E ratio, Hepion's valuation is highly dependent on the future success of Rencofilstat. Not financial advice.
How frequently does HEPA data refresh on this page?
HEPA's price is the last quote we recorded, from the Oct 26, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven HEPA's recent stock price performance?
Hepion Pharmaceuticals, Inc. (HEPA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary drug candidate (Rencofilstat) with a novel mechanism of action. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HEPA overvalued or undervalued right now?
Hepion Pharmaceuticals, Inc. (HEPA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HEPA before investing?
Before investing in Hepion Pharmaceuticals, Inc. (HEPA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on limited data provided.
- CEO background information is not available.